Evidence mapPaperPMID 40099997Full record

ArticleChemMedChem2025

Advances in Diclofenac Derivatives: Exploring Carborane-Substituted N-Methyl and Nitrile Analogs for Anticancer Therapy.

Christoph Selg, Robert Schuster, Aleksandr Kazimir, Peter Lönnecke, Mara Wolniewicz, Jonas Schädlich, Markus Laube, Jens Pietzsch, Vuk Gordić, Tamara Krajnović and 3 more

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christoph SelgFaculty of Chemistry and Mineralogy, Institute of Bioanalytical Chemistry, Leipzig University, Deutscher Platz 5, 04103, Leipzig, Germany.
Robert SchusterFaculty of Chemistry and Mineralogy, Institute of Bioanalytical Chemistry, Leipzig University, Deutscher Platz 5, 04103, Leipzig, Germany.
Aleksandr KazimirInstitute for Drug Discovery, Leipzig University, Brüderstraße 34, 04103, Leipzig, Germany.
Peter LönneckeFaculty of Chemistry and Mineralogy, Institute of Bioanalytical Chemistry, Leipzig University, Deutscher Platz 5, 04103, Leipzig, Germany.
Mara WolniewiczFaculty of Chemistry and Mineralogy, Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103, Leipzig, Germany.
Jonas SchädlichDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328, Dresden, Germany.
Markus LaubeDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328, Dresden, Germany.
Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328, Dresden, Germany.
Vuk GordićDepartment of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of the Republic of Serbia, University of Belgrade, 11108, Belgrade, Serbia.
Tamara KrajnovićDepartment of Chemistry, Babeş-Bolyai University, Str. Arany Janos Nr. 11, RO-400028, Cluj-Napoca, Romania.
Sanja MijatovićDepartment of Chemistry, Babeş-Bolyai University, Str. Arany Janos Nr. 11, RO-400028, Cluj-Napoca, Romania.
Danijela Maksimović-IvanićDepartment of Chemistry, Babeş-Bolyai University, Str. Arany Janos Nr. 11, RO-400028, Cluj-Napoca, Romania.
Evamarie Hey-HawkinsFaculty of Chemistry and Mineralogy, Institute of Bioanalytical Chemistry, Leipzig University, Deutscher Platz 5, 04103, Leipzig, Germany.ORCID https://orcid.org/0000-0003-4267-0603

Funding

Deutsche Forschungsgemeinschaft 1376/54-1Deutsche Forschungsgemeinschaft 314061271Deutsche Forschungsgemeinschaft SA 2902/2-1European Union NextGenerationEU PNRR-III-C9-2023-I8-CF76Ministry of Science, Technological Development, and Innovation 451-03-136/2025-03/200007
6 · The paper itself

Abstract

This study explores the anticancer potential of N-methylated open-ring derivatives of carborane-substituted diclofenac analogs. By N-methylation, the open-chain form could be trapped and cyclization back to lactam or amidine derivatives is inhibited. A small library of carborane- and phenyl-based secondary and tertiary arylamines bearing carboxylic acid or nitrile groups is synthesized and analyzed for their COX affinity in vitro and in silico. The compounds are further evaluated against mouse adenocarcinoma (MC38), human colorectal carcinoma (HCT116), and human colorectal adenocarcinoma (HT29) cell lines and show potent cytotoxicity. Additional biological assessments of the mode of action are performed using flow cytometric techniques and fluorescence microscopy. The data obtained reveal a common antiproliferative effect coupled with the induction of caspase-independent apoptosis and the specific effects of the compound on the phenotype of MC38 cells, resulting in impaired cell viability of MC38 cells and satisfactory selectivity exceeding the antitumor activity of diclofenac.

Indexed as

Antineoplastic AgentsBoranesDiclofenacNitrilesAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBoranesDiclofenacNitrilesaryl mimetic replacementscancerscarboranescyclooxygenasesdrug repurposing

Identifiers

PMID40099997
PMCPMC12132914

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.